Elvitegravir cobicistat emtricitabine tenofovir indications and usage: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Elvitegravir cobicistat emtricitabine tenofovir}} {{CMG}}; {{AE}} {{MM}} ==Indications and Usage== STRIBILD® is indicated as a complete regimen for the treatment...") |
|||
| Line 4: | Line 4: | ||
==Indications and Usage== | ==Indications and Usage== | ||
STRIBILD® is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74ae2a93-b267-444c-8f0f-a2a6522260ee | publisher = | date = | accessdate}}</ref> | STRIBILD® is indicated as a complete regimen for the treatment of [[HIV]]-1 infection in adults who are antiretroviral treatment-naïve.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74ae2a93-b267-444c-8f0f-a2a6522260ee | publisher = | date = | accessdate}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 17:52, 17 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Indications and Usage
STRIBILD® is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve.[1]
References
Adapted from the FDA Package Insert.